J&J’s Antibiotic Drug Levaquin Gains a Dozen Generic Competitors

The FDA announced the first approvals of generic versions of Johnson & Johnson’s (J&J) blockbuster antibiotic Levaquin, as the product loses its exclusivity. Levaquin (levofloxacin) garnered $1.4 billion in sales for J&J last year.
Generic Line